Data Insights

Alintegimod by 7 Hills Pharma for Colorectal Cancer: Likelihood of Approval

Alintegimod is under clinical development by 7 Hills Pharma and currently in Phase II for Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Alintegimod in Colorectal Cancer

Data Insights

Alintegimod by 7 Hills Pharma for Melanoma: Likelihood of Approval

Alintegimod is under clinical development by 7 Hills Pharma and currently in Phase II for Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Alintegimod in Melanoma

Data Insights

Alintegimod by 7 Hills Pharma for Hepatocellular Carcinoma: Likelihood of Approval

Alintegimod is under clinical development by 7 Hills Pharma and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Alintegimod in Hepatocellular Carcinoma

Data Insights

Alintegimod by 7 Hills Pharma for Renal Cell Carcinoma: Likelihood of Approval

Alintegimod is under clinical development by 7 Hills Pharma and currently in Phase II for Renal Cell Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Alintegimod in Renal Cell Carcinoma

Data Insights

Alintegimod by 7 Hills Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval

Alintegimod is under clinical development by 7 Hills Pharma and currently in Phase II for Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Alintegimod in Non-Small Cell Lung Cancer

Data Insights

Alintegimod by 7 Hills Pharma for Malignant Pleural Mesothelioma: Likelihood of Approval

Alintegimod is under clinical development by 7 Hills Pharma and currently in Phase II for Malignant Pleural Mesothelioma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Alintegimod in Malignant Pleural Mesothelioma